# Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

> **NCT00948922** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 124 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Melphalan
- **PROCEDURE:** Autologous Stem Cell Transplant
- **DRUG:** Fludarabine
- **PROCEDURE:** Allogeneic Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00948922
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-18
- **Primary completion:** 2017-04-20
- **Final completion:** 2019-05-14
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2019-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948922, "Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00948922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*